Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Effect of the peroxisorne proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus (2005)

  • Authors:
  • USP affiliated authors: HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF ; HIRATA, MARIO HIROYUKI - FCF
  • USP Schools: FCF; FCF
  • DOI: 10.1007/bf03345355
  • Subjects: POLIMORFISMO; DIABETES MELLITUS; GENÓTIPOS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/bf03345355 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Journal of Endocrinological Investigation

    ISSN: 0391-4097

    Citescore - 2017: 2.65

    SJR - 2017: 1.076

    SNIP - 2017: 1.094


  • How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TAVARES, Vladimir; HIRATA, Rosario Dominguez Crespo; RODRIGUES, Alice Cristina; et al. Effect of the peroxisorne proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. Journal of Endocrinology Investigation, Milan, v. 28, n. 2, p. 129-136, 2005. DOI: 10.1007/bf03345355.
    • APA

      Tavares, V., Hirata, R. D. C., Rodrigues, A. C., Monte, O., Salles, J. E. N., Scallissi, N., et al. (2005). Effect of the peroxisorne proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. Journal of Endocrinology Investigation, 28( 2), 129-136. doi:10.1007/bf03345355
    • NLM

      Tavares V, Hirata RDC, Rodrigues AC, Monte O, Salles JEN, Scallissi N, Speranza AC, Gomes S, Hirata MH. Effect of the peroxisorne proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. Journal of Endocrinology Investigation. 2005 ; 28( 2): 129-136.
    • Vancouver

      Tavares V, Hirata RDC, Rodrigues AC, Monte O, Salles JEN, Scallissi N, Speranza AC, Gomes S, Hirata MH. Effect of the peroxisorne proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. Journal of Endocrinology Investigation. 2005 ; 28( 2): 129-136.

    Referências citadas na obra
    Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001, 60(Suppl 1): 14–30.
    Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 1995, 92: 7921–5.
    Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J of Biol Chem 1997, 272: 18779–789.
    Fajas L, Fruchart JC, Auwerx J. PPARgamma3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 1998, 438: 55–60.
    Berger J, Moller DE. The mechanism of action of PPARs. Annu Rev of Med 2002, 53: 409–35.
    Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001, 276: 41245–54.
    Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000, 105: 287–92.
    Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999, 42: 1033–49.
    Hulin B, McCarthy PA, Gibbs EM. The glitazone family of antidiabetic agents. Current Pharmaceutical Designs 1996, 2: 85–102.
    Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39: 665–8.
    Meirhaeghe A, Fajas L, Helbecque N, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998, 7: 435–40.
    Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor γ C161T polymorphism and coronary artery disease. Cardiovasc Res 1999, 44: 588–94.
    Blüher M, Klemm T, Gerike T, Krankenberg H, Schuler G, Paschke R. Lack of association between peroxisome proliferator-activated receptor-γ-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur J Endocrinol 2002, 146: 545–51.
    Poulsen P, Andersen G, Fenger M, et al. Impact of two common polymorphism in the PPARγ gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins. Diabetes 2003, 52: 194–8.
    Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocytes differentiation. N Engl J Med 1998, 339: 953–9.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl 1): S5–S10.
    Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20: 537–44.
    Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Rastam L. Risk factor clustering in patients with hypertension and NIDDM. J Intern Med 1998, 243: 223–32.
    Östgren CJ, Lindblad U, Bog-Hansen E, Ranstam J, Melander A, Rastam L. Differences in treatment and metabolic abnormalities between normo and hypertensive patients with type 2 diabetes. Diabetes Obes Metab 1999, 1: 105–12.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499–502.
    Dobiasova M, Frohlich J. The plasma parameter log (TG/ HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001, 34: 583–8.
    Tan MH, Johns D, Glazer NB. Pioglitazone reduces Atherogenic Index of Plasma in patients with type 2 diabetes. Clin Chem 2004, 50: 1184–8.
    Bonora E, Saggiani F, Targher G, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23: 57–63.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.
    Salazar LA, Hirata MH, Cavalli SA, Machado MO, Hirata RDC. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998, 44:1748–50.
    Barroso I, Gurnell M, Crowley VEF, et al. Dominant negative mutation in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402: 880–3.
    Salazar LA, Hirata MH, Hirata RDC. Increasing the sensitivity of single-strand conformation polymorphism analysis of the LDLR gene mutations in Brazilian patients with familial hypercholesterolemia. Clin Chem Lab Med 2002, 40: 441–5.
    Cleeman J. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). The JAMA 2001, 285: 2486–97.
    World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894: 6–15.
    Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature 1998, 20: 284–7.